Trial reportClinical oral investigations2026
Salivary asprosin, IL-39, IL-40, and IL-1β levels in diabetic patients with periodontitis: A cross-sectional analysis.
Trial report in Clinical oral investigations, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06735313 (Evaluation of Salivary Asprosin, IL-39,IL-40 and IL-1β Levels in Diabetic Patients with Periodontitis), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Salivary Asprosin, IL-39,IL-40 and IL-1β Levels in Diabetic Patients with Periodontitis
Who cites it
1 citing paper in PubMed.
- From biological evidence to clinical application: a scoping review of oral fluid biomarkers in type 2 diabetic periodontitis.Frontiers in oral health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePeriodontitis and type 2 diabetes mellitus (T2DM) are chronic diseases with a well-established bidirectional relationship. Recent studies have focused on salivary biomarkers to better understand their shared inflammatory mechanisms. This study aimed to assess salivary levels of asprosin, interleukin (IL) -39, IL-40, and IL-1β in patients with and without periodontitis and/or diabetes. MATERIALS AND
methodsEighty-eight participants were classified into four groups based on periodontal and diabetic status. Unstimulated saliva samples were collected and analyzed by ELISA. In addition to clinical periodontal parameters, body mass index (BMI) and glycated hemoglobin (HbA1c) levels were recorded.
resultsSalivary asprosin and IL-1β levels were elevated in periodontitis groups regardless of T2DM status and showed positive correlations with BMI. IL-39 showed no significant findings. All biomarkers, with the exception of IL-39, were positively correlated with clinical periodontal parameters. IL-40 was elevated in both diabetic and non-diabetic patients with periodontitis.
conclusionsElevated salivary asprosin, IL-40, and IL-1β levels in diabetic individuals with periodontitis may indicate their involvement in the inflammatory interactions linking metabolic dysfunction and periodontal tissue breakdown. IL-39 showed limited utility. These findings enhance understanding of salivary inflammatory patterns in diabetes-associated periodontitis, although the saliva-only, cross-sectional design warrants cautious interpretation. CLINICAL RELEVANCE: The identification of salivary asprosin, IL-40, and IL-1β as potential indicators of periodontal and metabolic inflammation suggests that saliva-based testing could support non-invasive screening and monitoring in patients with diabetes and periodontitis. CLINICAL TRIAL NUMBER: NCT06735313.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.